Scholarlink

<p>This study examines the impact of SNPs in cytochrome P450 2C19, P-glycoprotein, and P2Y12 receptor genes on clopidogrel response in coronary patients. We conducted a cross-sectional study involving 135 acute coronary syndrome patients on clopidogrel. Platelet reactivity was assessed using the VerifyNow® P2Y12 test, with clopidogrel resistance defined as PRU ≥ 208. Genotyping was done by PCR–RFLP. Clopidogrel resistance was observed in 33% of patients. The <i>CYP2C19*2</i> polymorphism was associated with poor response (GA vs. GG; <i>p</i> = 0.048, OR 2.63, 95% CI 1.01–6.87). The <i>CYP2C19*</i>17 polymorphism was more common in responders (CT/TT vs. CC; <i>p</i> = 0.018, OR 0.35, 95% CI 0.14–0.87). No significant association was found for <i>ABCB1 (C3435T), P2Y12 (T744C),</i> or <i>ITGB3 (rs5918)</i> polymorphisms (<i>p</i> &gt; 0.05). Our results constitute preliminary proof for the implication of genetic polymorphisms in the response of platelet to clopidogrel in Tunisian coronary patients. Thus a prospective validation study is needed.</p><p> <?qj left?> <?noindent??><i>Clinical Trial Registration</i> This work is part of a study indexed under the number NCT03373552 of clinical trials on the site of the NIH (National Institutes of Health) of the United States "ClinicalTrials.gov" registered on December 14, 2017 and relates to the genetic polymorphisms associated with coronary heart disease susceptibility and variability of clopidogrel response. <i>URL of Trial Registry Record:</i> <a href="https://clinicaltrials.gov/study/NCT03373552">https://clinicaltrials.gov/study/NCT03373552</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Study of the Genetic Polymorphisms Involved in the Response of Platelet to Clopidogrel in Coronary Patients

  • 期刊论文

  • 发表日期：

    2025年11月13日

查看全文
  • Saoussen Chouchene,
  • Amani Abderahmene,
  • Hajer Foddha,
  • Asma Omezzine,
  • Rym Dabboubi,
  • Sondes Hadj Fredj,
  • Haythem Raddaoui,
  • Maroua Rezek,
  • Rania El Aissi,
  • Mayssa Gaaloul,
  • Rihem Mezrigui,
  • Yosra Gassara,
  • Taieb Messaoud,
  • Hassen Ben Abdennebi,
  • Khaldoun Ben Hamda,
  • Mohsen Hassine

摘要

This study examines the impact of SNPs in cytochrome P450 2C19, P-glycoprotein, and P2Y12 receptor genes on clopidogrel response in coronary patients. We conducted a cross-sectional study involving 135 acute coronary syndrome patients on clopidogrel. Platelet reactivity was assessed using the VerifyNow® P2Y12 test, with clopidogrel resistance defined as PRU ≥ 208. Genotyping was done by PCR–RFLP. Clopidogrel resistance was observed in 33% of patients. The CYP2C19*2 polymorphism was associated with poor response (GA vs. GG; p = 0.048, OR 2.63, 95% CI 1.01–6.87). The CYP2C19*17 polymorphism was more common in responders (CT/TT vs. CC; p = 0.018, OR 0.35, 95% CI 0.14–0.87). No significant association was found for ABCB1 (C3435T), P2Y12 (T744C), or ITGB3 (rs5918) polymorphisms (p > 0.05). Our results constitute preliminary proof for the implication of genetic polymorphisms in the response of platelet to clopidogrel in Tunisian coronary patients. Thus a prospective validation study is needed.

Clinical Trial Registration This work is part of a study indexed under the number NCT03373552 of clinical trials on the site of the NIH (National Institutes of Health) of the United States "ClinicalTrials.gov" registered on December 14, 2017 and relates to the genetic polymorphisms associated with coronary heart disease susceptibility and variability of clopidogrel response. URL of Trial Registry Record: https://clinicaltrials.gov/study/NCT03373552.